Loading clinical trials...

Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy

Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy: a Randomized Double-blind Placebo-controlled Study

NCT00371956•Tuen Mun Hospital

View on ClinicalTrials.gov

Summary

This study is a double-blind placebo-controlled trial evaluating the efficacy of raloxifene in the prevention of bone mineral density loss in patients receiving long term corticosteroids.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•1. Postmenopausal patients with various chronic rheumatic diseases receiving chronic steroid therapy.
•2. Stable disease for at least 6 months prior to study with a stable dose of steroid (prednisone \<= 10 mg/day or equivalent).
•3. Baseline bone mineral density (BMD) of the lumbar spine T score \< -1.0.

Exclusion Criteria

•1. Patients with a history of thromboembolism.
•2. Patients with positive antiphospholipid antibodies.
•3. History of allergic reactions or intolerance to raloxifene or other SERMs.
•4. Patients receiving bisphosphonates, parathyroid hormone, SERMs, anticonvulsants or anti-cytokine therapies within 6 months prior to study entry.
•5. Patients with known bone disorders such as osteomalacia, renal osteodystrophy, and hyperparathyroidism.
•6. Patients with abnormal uterine bleeding of unknown etiology.
•7. Patients with serum creatinine level of \>= 200 umol/L.

Locations (1)

Tuen Mun Hospital

Hong Kong, China

Key Dates

Start Date

September 1, 2006

Primary Completion Date

February 1, 2010

Completion Date

February 1, 2010

Last Updated

September 16, 2010

Enrollment

114

ACTUAL participants

Conditions

Osteoporosis

Interventions

raloxifene

DRUG

placebo

DRUG

OsteoPorotic fracTure preventION System (OPTIONS) Research Study

NCT06731608

OsteoporosisLower Limb Fracture

View study

RECRUITING

Smart Wearable Device (gaitQ): Walk Better Project

NCT05913219

Parkinson DiseaseStroke+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 16, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy

Inclusion Criteria

Exclusion Criteria

OsteoPorotic fracTure preventION System (OPTIONS) Research Study

Smart Wearable Device (gaitQ): Walk Better Project

Step-down Therapy After Long-term Osteoporosis Treatment

Automated Bone Age Estimation From Noncontrast Abdominal CT Using Deep Learning

Effect of Mechanical Loading and Bone Loss on Motor Neuron Activity-H-Reflex Relationship

Clinical Study to Estimate Bone Mineral Density With the POROUS Ultrasound Device